Home/Filings/4/0001213900-20-016303
4//SEC Filing

Zarrabian Saiid 4

Accession 0001213900-20-016303

CIK 0001498382other

Filed

Jun 29, 8:00 PM ET

Accepted

Jun 30, 4:08 PM ET

Size

5.8 KB

Accession

0001213900-20-016303

Insider Transaction Report

Form 4
Period: 2019-09-05
Zarrabian Saiid
DirectorInterim CEO
Transactions
  • Award

    Options (Right to Buy)

    2020-06-26+241,438457,650 total
    Exercise: $0.61Exp: 2029-09-05Common Stock (241,438 underlying)
Footnotes (2)
  • [F1]On September 5, 2019, the reporting person received options to purchase 241,438 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020.
  • [F2]1/6th of the options vested on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 5, 2020.

Documents

1 file

Issuer

DelMar Pharmaceuticals, Inc.

CIK 0001498382

Entity typeother

Related Parties

1
  • filerCIK 0001495521

Filing Metadata

Form type
4
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 4:08 PM ET
Size
5.8 KB